A Study to Assess Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Chinese Participants Receiving Upadacitinib for Atopic Dermatitis (AD) Through Chart Review

AbbVie

Status

Completed

Conditions

Atopic Dermatitis (AD)

Study type

Observational

Funder types

Industry

Identifiers

NCT06503536

H24-962

Details and patient eligibility

About

Atopic Dermatitis (AD) is a common, chronic, and flaring systemic inflammatory skin disorder characterized by intensely pruritic and distressing skin eruptions. This study will assess treatment patterns, treatment outcomes, healthcare resource utilization in Chinese participants receiving Upadacitinib for Atopic Dermatitis (AD) undergoing chart review.

Enrollment

150 patients

Sex

All

Ages

12+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Participants with at least one primary diagnosis of atopic dermatitis with ICD-10 code of L20.900 [atopic dermatitis, unspecified] or physician-confirmed atopic dermatitis documentation within the study period
Participants with at least one documented health record of upadacitinib prescription that has a primary diagnosis of atopic dermatitis within the study period
Participants with at least one atopic dermatitis severity measures (i.e., EASI) in the follow-up period including up to 6 months after the index date

Exclusion criteria

• Participants who did not fulfill the inclusion criteria will be excluded